华润双鹤药业2026年第一季度报告深度解读：营收利润下滑，10亿元科创债发行

一、核心要点概述

• 营收与利润均出现下滑——2026年第一季度营业收入同比下降8.84%，归属于上市公司股东的净利润同比下降4.30%。
• 经营现金流大幅减少——经营活动产生的现金流量净额同比大跌46.19%。
• 资产规模继续扩张——总资产同比增长5.87%，归属于上市公司股东的所有者权益增长4.17%。
• 成功发行10亿元科技创新公司债——2026年3月26日完成面向专业投资者公开发行的10亿元三年期科技创新公司债券，票面利率1.65%。

二、财务数据详细解读

主要变动原因

公司指出，现金流量净额下滑主要原因在于销售回款放缓，以及预付产品引进和采购物料货款增加。此外，营业成本和销售费用有所下降，但管理费用和研发投入保持高位。整体利润下滑幅度小于收入降幅，说明部分成本费用得到控制。

三、非经常性损益明细

• 本期非经常性损益合计1,593.56万元，主要来自政府补助和非流动资产处置收益。
• 主要项目包括：政府补助1,816万元，资产处置损益162万元，金融资产公允价值变动146万元等。

四、股东结构与资本动态

• 公司大股东为北京医药集团有限责任公司，持股比例高达60.25%，无质押、冻结等异常情况。
• 前十大股东结构稳定，香港中央结算有限公司为第二大股东。
• 报告期内未有转融通出借股份情况。

五、重大事项及潜在股价影响点

• 10亿元科技创新公司债券成功发行：本期债券简称“26润鹤K1”，债券代码“244850.SH”，期限3年，票面利率1.65%。本次发行极大提升公司资金实力，有助于加快科技创新项目建设，改善资本结构，对未来发展有积极意义，有望提升市场信心，成为潜在的股价催化剂。

• 业绩下滑需警惕：营收与净利润同比下降，且现金流大幅下滑，显示公司主业短期承压，需关注下游需求、产品结构调整及费用管控等后续进展，若短期内未见改善，或对公司估值形成压力。

六、财务报表要点

• 资产负债表显示公司流动资产充足，货币资金较年初大幅增加，反映债券发行带来的资金流入。
• 流动负债结构中短期借款下降，长期借款大幅减少，应付债券增加10亿元，表明债务结构优化。
• 现金流量表显示投资活动现金流转正，主要因投资回收和资产处置收益，筹资活动现金流大幅回正，得益于新债券发行。

七、投资者关注事项

• 公司主营业务承压，需持续关注后续营收、利润恢复情况。
• 10亿元债券发行改善流动性，有望支持公司研发及扩张计划。
• 公司资产和资本结构稳健，财务风险可控。

八、结论

本次一季报显示华润双鹤短期内业绩承压，但公司通过大规模债券融资增强资金实力，具备较强的抗风险能力和持续发展潜力。投资者应关注业务调整、现金流恢复及新项目进展，短期业绩波动和融资举措均为潜在股价影响因素。

免责声明： 本文仅为公开财报信息的深度解读，不构成任何投资建议。投资有风险，决策需谨慎。

English Version

China Resources Double-Crane Pharma Q1 2026: Revenue & Profit Decline, 1 Billion CNY Tech Bond Issued

Key Highlights

• Revenue and Profit Decline — Q1 2026 revenue down 8.84% YoY; net profit attributable to shareholders down 4.30% YoY.
• Operating Cash Flow Drops Sharply — Net cash from operating activities fell 46.19% YoY.
• Asset Base Expands — Total assets up 5.87% YoY; equity attributable to shareholders up 4.17%.
• 1 Billion CNY Tech Innovation Bond Issued — 3-year maturity, 1.65% coupon, boosting liquidity and supporting R&D and expansion.

Detailed Financial Analysis

Main Change Drivers

The company attributed the cash flow drop to slower sales collection and increased prepayments for product introductions and materials procurement. Cost and selling expenses declined, but management and R&D costs remained high. Profit fell less than revenue, indicating some cost control.

Non-recurring Profit & Loss

• Non-recurring gains totaled 15.94 mn CNY, mostly from government subsidies and asset disposals.
• Key contributors: government subsidies (18.16 mn CNY), asset disposal (1.62 mn CNY), financial asset fair value changes (1.46 mn CNY), etc.

Shareholder Structure & Capital Moves

• Beijing Pharmaceutical Group holds a dominant 60.25% stake, with no pledges or freezes.
• Top 10 shareholders stable; Hong Kong Securities Clearing the second-largest.
• No share lending through margin or securities lending this period.

Major Developments & Potential Market Impact

• 1 Billion CNY Tech Innovation Bond Issued: “26润鹤K1” (code: 244850.SH), 3-year term, 1.65% coupon. This strengthens the company’s liquidity, supports innovation projects, and optimizes capital structure. It could boost market confidence and act as a positive share price catalyst.
• Performance Pressure: Revenue/profit decline and cash flow drop show short-term business pressure. Investors should watch for demand recovery, product mix, and cost control progress. Prolonged weakness could weigh on valuation.

Financial Statement Highlights

• Ample current assets, with cash positions boosted by the bond issue.
• Short-term borrowings fell, long-term borrowings dropped, and bonds payable rose by 1 bn CNY, indicating improved debt structure.
• Investment cash flow turned positive due to asset disposals and returns; financing cash flow was strongly positive thanks to the new bond.

Investor Focus

• Business faces short-term headwinds; monitor revenue and profit recovery.
• Bond issuance improves liquidity, supporting R&D and expansion plans.
• Asset and capital structure remain solid, with manageable financial risk.

Conclusion

Q1 2026 results reveal near-term challenges for China Resources Double-Crane, but the successful bond issue bolsters financial resilience and long-term prospects. Investors should track business recovery, cash flow trends, and project execution. Both recent earnings volatility and funding moves are potential market movers.

Disclaimer: This article is an in-depth interpretation of public financial reports and does not constitute investment advice. Investment carries risk—please make decisions prudently.

View 华润双鹤 Historical chart here